Author(s):
Manoj Shantilala Patil, Mohit Sunil Pawar, Sunila A Patil, Sunil P. Pawar
Email(s):
manojspatil632@gmail.com
DOI:
10.52711/2231-5675.2025.00034 
Address:
Manoj Shantilala Patil*, Mohit Sunil Pawar, Sunila A Patil, Sunil P. Pawar
P.S.G.V.P Mandal’s College of Pharmacy Shahada, Dist- Nandurbar- 425409, Maharashtra-India.
*Corresponding Author
Published In:
Volume - 15,
Issue - 3,
Year - 2024
ABSTRACT:
This comprehensive review explores garenoxacin, a novel des-fluoro (6) quinolone antibiotic, highlighting its pharmacological properties, clinical applications, and analytical methodologies. Garenoxacin exhibits broad-spectrum antibacterial activity against both Gram-positive and Gram-negative organisms, including drug-resistant strains. Its mechanism involves dual inhibition of DNA gyrase and topoisomerase IV, making it a potent candidate for treating skin and soft tissue infections (SSSIs), respiratory tract infections, and other microbial conditions. The paper examines garenoxacin's pharmacokinetics, protein binding. Pharmacodynamic analyses show that AUC/MIC ratios are critical for efficacy. Analytical techniques such as HPLC, UHPLC, RP-HPLC, and UV-spectrophotometry are discussed in the context of garenoxacin quantification and validation, with emphasis on ICH and QbD guidelines. Clinical cases and studies underscore its effectiveness, safety, and occasional adverse reactions, including hypersensitivity and fixed drug eruptions. The review also includes method development for pharmacokinetic studies and dosage form analysis, establishing garenoxacin’s significance in therapeutic and analytical fields.
Cite this article:
Manoj Shantilala Patil, Mohit Sunil Pawar, Sunila A Patil, Sunil P. Pawar. Comprehensive Review on Garenoxacin: Pharmacological Profile, Analytical Methods, and Clinical Application. Asian Journal of Pharmaceutical Analysis. 2025; 15(3):213-0. doi: 10.52711/2231-5675.2025.00034
Cite(Electronic):
Manoj Shantilala Patil, Mohit Sunil Pawar, Sunila A Patil, Sunil P. Pawar. Comprehensive Review on Garenoxacin: Pharmacological Profile, Analytical Methods, and Clinical Application. Asian Journal of Pharmaceutical Analysis. 2025; 15(3):213-0. doi: 10.52711/2231-5675.2025.00034 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2024-15-3-10
REFERENCES
1. Ince D, Zhang X, Silver LC, Hooper DC. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob Agents Chemother. 2002; 46(11): 3370-80.
2. Lipsky BA. Evidence-based antibiotic therapy of diabetic foot infections. FEMS Immunol Med Microbiol.
3. Woods RK, Dellinger EP. Current guidelines for antibiotic prophylaxis of surgical wounds. Am Fam Physician. 1998; 57(11): 2731-40.
4. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med. 1996; 334(4): 240-5.
5. Janda JM, Abbott SL, Brenden RA. Overview of the etiology of wound infections with particular emphasis on community-acquired illnesses. Eur J Clin Microbiol Infect Dis. 1997; 16(3): 189-201.
6. Liebetrau A, Rodloff AC, Behra-Miellet J, Dubreuil L: In vitro activities of a new des-fluoro (6) quinolone, garenoxacin, against clinical anaerobic bacteria. Antimicrob Agents Chemother. 2003, 47: 3667-71.10.1128/AAC.47.11.3667-3671.2003
7. Takahata M, Mitsuyama J, Yamashiro Y, Yonezawa M, Araki H, et al. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob Agents Chemother. 1999; 43: 1077-1084.
8. Fung-Tomc JC, Minassian B, Kolek B, Huczko E, Aleksunes L, et al. (2000) Antibacterial spectrum of a novel des-fluoro (6) quinolone, BMS-284756.Antimicrob Agents Chemother 44: 3351-3356.
9. Nord CE, Gajjar DA, Grasela DM. Ecological impact of the des-F (6)-quinolone, BMS-284756, on the normal intestinal microflora. Clin Microbiol Infect. 2002; 8: 229-239.
10. Ishii Y. Antibiotic susceptibility testing and breakpoint. –Their problems and future prospects– JPN J Chemother. 2011; 59:454–59. Japanese.
11. Anon, Schering-Plough Reports Garenoxacin NDA Accepted for FDA Review. Available at: http://www.drugs.com/nda/garenoxacin_060213.html [Accessed December 10, 2015].
12. A. Unnisa, S.S. Ali and K.S.C., World J. Pharm. Pharmaceut. Sci. 2014; 3: 1767.
13. Jones RN, Fritsche TR, Sader HS, et al. Garenoxacin (BMS-284756): In Vitro Antimicrobial Spectrum, Mechanisms of Action, and Resistance Development. Clinical Infectious Diseases. 2005; 41(Suppl 2): S87–S98.
14. Hooper DC. Mechanisms of Action of Antimicrobial Agents. Principles and Practice of Infectious Diseases, 8th ed. Elsevier, 2015.
15. D. A. Gajjar, A. Bello, Z. Ge, L. Christopher, and D. M. Grasela, Multiple-Dose Safety and Pharmacokinetics of Oral Garenoxacin in Healthy Subjects, DOI: 10.1128/AAC.47.7.2256–2263.2003 Vol. 47, No. 7
16. Scott Van Wart, Luann Phillips, Elizabeth A. Ludwig, Rene Russo, Diptee A. Gajjar, Akintunde Bello, Paul G. Ambrose, Christopher Costanzo, Thaddeus H. Grasela, Roger Echols, and Dennis M. Grasela, Population Pharmacokinetics and Pharmacodynamics of Garenoxacin in Patients with Community-Acquired Respiratory Tract Infections, DOI: 10.1128/AAC.48.12.4766–4777.2004, Vol. 48, No. 12
17. D. Andes, W. A. Craig, Pharmacodynamics of the New Des-F(6)-Quinolone Garenoxacin in a Murine Thigh Infection Model. 2003; 47(12). doi.org/10.1128/aac.47.12.3935-3941.2003
18. Chauhan A, Mittu B, Chauhan P. Analytical method development and validation: a concise review. J Anal Bioanal Tech. 2015; 6(1): 1-5.
19. Skoog. D. A, Holler. F. G, Nieman.T.A. Principles of Instrumental Analysis.5th Edition, Thomson Brooks/Cole Asia Pvt. Ltd., Singapore. 2004, 4-7.
20. Willard. H. H, Meritt, L. L, Dean, J. A, Settle. F. A. Instrumental Methods of Analysis. 7th Edition, CBS Publishers and Distributors, New Delhi. 8-10
21. Chatwal. G. R, Anand. S. K. Instrumental Methods of Chemical Analysis. 5th Edition, Himalaya Publishing House, New Delhi. 2007; 2; 624-2.629 5.
22. Sethi. P. D. High Performance Liquid Chromatography. 1st Edition, CBS Publishers and Distributors, New Delhi, 2001, 12-15. 6.
23. Raymond P. W, Principles and Practices of Chromatography, Chrom-Edbook series,2003,1-15 7.
24. Snyder. L. R., Glajch, J. L, Kirkland. J. J. Practical HPLC Method Development. 2 nd Edition, John Wiley & Sons, Inc. A Wiley-interscience Publication, USA.1997: 7-15.
25. Chung C. C, Herman. L, Lee Y.C, Xue-Ming Zang. Analytical Method Validation and Instrument Performance Verification. A John Wiley & Sons, Inc., Publication,2004,11-12
26. Takagi H, Tanaka K, Tsuda H, Kobayashi H Clinical studies of garenoxacin. Int J Antimicrob Agents 2008; 32:468-74.
27. Fung-Tomc JC, Minassian B, Kolek B, Huczko E, Aleksunes L, Stickle T, et al. Antibacterial spectrum of a novel des-fluoro (6) quinolone, BMS- 284756. Antimicrob Agents Chemother. 2000; 44: 3351-6.
28. Natsumi Hara, Natsuko Saito-Sasaki, Yu Sawada Fixed Drug Eruption Caused by Garenoxacin: A Case Report and Literature Review Doi: 10.7759/cureus.48596 2023
29. Yoko Matsuda, Yoshitsugu Chigusa, Eiji Kondoh, Isao Ito, Yusuke Ueda, and Masaki Mandai A Case of Macrolide-Refractory Mycoplasma pneumoniae Pneumonia in Pregnancy Treated with Garenoxacin Volume 2017, Article ID 3520192, 4 pages doi.org/10.1155/2017/3520192
30. Mushino T, Hanaoka N, Murata S, Kuriyama K, Hosoi H, Nishikawa A, Tamura S, Nakakuma H, and Sonoki T, An Optimal Approach for Fluoroquinolone Garenoxacin Prophylaxis in Patients with Hematological Malignancies and Chemotherapy-induced Neutropenia. 2017; 7: 1 DOI: 10.4172/2165-7831.1000161, Volume 7
31. Yuka Yamagishi, Tatsuya Shibata, Satoshi Nakagawa, Nobuhiko Nomura, Junichi Mitsuyama, and Hiroshige Mikamo, Proposed pharmacokinetic–pharmacodynamic breakpoint of garenoxacin and other quinolones, DOI: 10.7883/yoken.JJID.2017.068
32. Yoshio Kawakami, Seiko Mitsui and Kosuke Oka, A Case of Anaphylaxis Following Administration of Garenoxacin Mesylate Hydrate, DOI: 10.4172/2155-9554.1000411. 8(5): 1000411
33. Rajendra B. Kakde, Krutika Warthi, Rahul P. Chilbule, Solid Phase Extraction-HPLC Method for Determination and Pharmacokinetic Study of Garenoxacin in Rat Plasma after Oral Administration. 2017; 10(2): 62-68 http://dx.doi.org/10.20902/IJPTR.2017.1019
34. Pravati Dutta, Shreyas Lathi, K Krishnaprasad, Amit Bhargava, Clinical utility of Garenoxacin in Lower Respiratory Tract Infections: A Retrospective Analyzes: A Case-Cohort Stud, DOI: 10.17354/ijss/2016/02 January 2016 | Vol 3 | Issue 10
35. A. P. Edlabadkar and A. P. Rajput, Development of Four Simple UV-Spectrophotometry Methods for Estimation of Garenoxacin Mesylate in Bulk Material and in Pharmaceutical Formulation, 2016, 8 (11): 213-217
36. Ajitha Azhakesan and Sujatha Kuppusamy, QbD-Based Development and Validation of Novel Stability-Indicating Method for the Assay and Dissolution of Garenoxacin in Garenoxacin Tablets. 2022; 105(2); 78 https://doi.org/10.1093/jaoacint/qsab157
37. Ajitha A, Sujatha K, Abbulu K, Bioanalytical method development and validation of garenoxacin mesylate in human plasma by RP-HPLC. 10(2): 1314-1320
38. Aboli Edlabadkar, Ambarsing Rajput, A QbD Approach- RP-HPLC Method for Optimization, Development and Validation of Garenoxacin Mesylate in Bulk and in Tablets. 2018; 13(4): em26